MiMedx Group, an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, has signed a definitive agreement to acquire Surgical Biologics, a provider in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
Surgical Biologics, through its proprietary tissue processing technology Purion, has differentiated itself, and its tissues in over 30,000 implants.
The Purion process follows strict guidelines for allograft processing established by the US Food and Drug Administration and the American Association of Tissue Banks (AATB).
MiMedx president and chief operating officer Bill Taylor said they will have three very exciting biomaterial platforms to offer to physicians and our distribution networks.
"Adding Surgical Biologics is a synergistic fit for the areas of medical care that MiMedx is addressing. For example, our HydroFix Vaso Shield product is a permanent and biocompatible vessel cover. We believe there are applications using the Purion tissue allograft as a resorbable vessel cover," Taylor said.
"Similarly, the potential applications of the Purion tissue processing technology for soft tissue repair could give us offerings that are extremely complementary to our planned CollaFix products.
"By adding the Purion technology to our existing platforms, we could have product or tissue offerings with distinctly different degradation profiles designed to fit the surgeon’s preference based on the specific repair."